European multicenter study of ET-COVID-19
… with the coronavirus disease 2019 (COVID-19) infection. … patients with COVID-19 are
substantially unknown. Our aim was to study early outcomes after MT in patients with COVID-19…
substantially unknown. Our aim was to study early outcomes after MT in patients with COVID-19…
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial
T Sonnweber, S Sahanic, A Pizzini… - European …, 2021 - Eur Respiratory Soc
… Conclusion A relevant percentage of post-COVID-19 patients presented with persisting
symptoms and lung function impairment along with radiological pulmonary abnormalities >100 …
symptoms and lung function impairment along with radiological pulmonary abnormalities >100 …
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
JC Tardif, N Bouabdallaoui, PL L'allier… - The Lancet …, 2021 - thelancet.com
… therapies to prevent COVID-19 complications in community-treated patients, the burden on
… the benefit of colchicine in patients with PCR-proven COVID-19, we propose that colchicine …
… the benefit of colchicine in patients with PCR-proven COVID-19, we propose that colchicine …
[HTML][HTML] Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Y Wang, D Zhang, G Du, R Du, J Zhao, Y Jin, S Fu… - The lancet, 2020 - thelancet.com
… In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not
associated with statistically significant clinical benefits. However, the numerical reduction in …
associated with statistically significant clinical benefits. However, the numerical reduction in …
Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults
F Ader - BMJ open, 2020 - bmjopen.bmj.com
… Moreover, by including patients at different times in their clinical history of COVID-19, we
will be able to study when is the best time to start an antiviral agent in relation to the delay of …
will be able to study when is the best time to start an antiviral agent in relation to the delay of …
… COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
SF Oosting, AAM van der Veldt… - The Lancet …, 2021 - thelancet.com
… Patients with cancer have an increased risk of complications from SARS-CoV-… COVID-19
is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for patients …
is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for patients …
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
… We did a retrospective, observational, multicentre cohort study at the 13 hospitals within the
… patients with COVID-19 who received ICU support. Our selection criteria were adult patients (…
… patients with COVID-19 who received ICU support. Our selection criteria were adult patients (…
High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: Multicentre randomized controlled clinical trial
J Mariani, L Antonietti, C Tajer, L Ferder, F Inserra… - PLoS …, 2022 - journals.plos.org
… The CholecAlcifeRol to improvE the outcomes of patients with COVID-19 (CARED) trial
was a multicentre, randomized, double-blind, sequential, placebo-controlled trial, designed by …
was a multicentre, randomized, double-blind, sequential, placebo-controlled trial, designed by …
Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE)
… conclusions In our multicentre pragmatic randomised clinical trial of encouraging prone
positioning in patients admitted to hospital with covid-19 who were hypoxaemic but not critically …
positioning in patients admitted to hospital with covid-19 who were hypoxaemic but not critically …
… of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
… published randomised trials of TNF inhibitors in COVID-19. … randomised trial of namilumab
and infliximab in COVID-19. … —in hospitalised patients with COVID-19 pneumonia. Secondary …
and infliximab in COVID-19. … —in hospitalised patients with COVID-19 pneumonia. Secondary …